• Lantern Pharma and NCI expand oncology partnership pharmaceutical-business-review
    January 13, 2022
    Lantern Pharma and the US National Institutes of Health unit National Cancer Institute’s (NCI) Developmental Therapeutics Branch (DTB) have announced...
  • Lantern Pharma Reacquires Irofulven from Allarity Therapeutics contractpharma
    July 29, 2021
    ​Allarity Therapeutics A/S and Lantern Pharma Inc. have entered an exclusive agreement under which Lantern will reacquire global rights to Irofulven (LP-100) and assume full responsibility for future clinical development and commercialization.
PharmaSources Customer Service